Click on image to view larger version.

Figure 2 (A) Long-term (7-year) survival in patients with idiopathic pulmonary arterial hypertension (IPAH) based on functional class (III vs. IV) at the time of epoprostenol initiation. p = 0.0001 by log-rank test (30). (B) Survival in patients with IPAH treated with intravenous epoprostenol according to New York Heart Association (NYHA) functional class. Estimated percentages of survival for patients in NYHA functional class IV at baseline (dashed line) were 76%, 60%, and 47% at one, two, and three years, respectively, as compared with 90%, 76%, and 71% for patients in NYHA functional class III at baseline (solid line) (p < 0.001 by the Cox-Mantel log-rank test) (32).